Corrigendum
In the Drug Evaluation “The role of gefitinib in the management of Asian patients with non-small cell lung cancer”, by A Chang, published in the March 2008 issue of Expert Opinion on Investigational Drugs (Expert Opin. Invest. Drugs (2008) 17(3):401-11), it has been noted that sentence 5 of the abstract should have read as follows:
Gefitinib was the first EGFR tyrosine kinase inhibitor approved for treating advanced NSCLC.
The authors and publishers sincerely regret any inconvenience that this error may have caused.